Organon and Sareum announce research collaboration in autoimmune disease

20-Jan-2006

Organon, the human health care business unit of Akzo Nobel, and Sareum Holdings plc, specialist structure-based drug discovery and services business, announced a collaborative research agreement. The aim of this collaboration, in which Sareum will potentially dedicate a multi-disciplinary research team for over one year, is to generate lead chemical series for development by Organon into novel therapies for autoimmune diseases such as rheumatoid arthritis.

Sareum will endeavor to determine the three-dimensional structures of two of the Organon autoimmune disease protein targets and then deploy its innovative Template Screening method to identify novel compounds suitable for optimization into lead drug candidates, using its automated medicinal chemistry platform. In return, Sareum will receive research fees and success milestone payments. Financial details were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...